Search
Cardiolipin Biosynthesis CL(10:0/a-17:0/i-20:0/i-20:0)
smpdb.ca/view/SMP0180063MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/i-12:0/i-20:0/i-20:0)
smpdb.ca/view/SMP0180606MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/i-13:0/i-20:0/i-20:0)
smpdb.ca/view/SMP0181012MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/i-14:0/i-20:0/i-20:0)
smpdb.ca/view/SMP0181363MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/i-17:0/i-20:0/i-20:0)
smpdb.ca/view/SMP0182041MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/i-20:0/i-20:0/a-21:0)
smpdb.ca/view/SMP0182332MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/i-20:0/i-20:0/a-25:0)
smpdb.ca/view/SMP0182333MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/i-20:0/i-20:0/i-22:0)
smpdb.ca/view/SMP0182336MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Acoramidis
go.drugbank.com/drugs/DB17999ApprovedInvestigational[A264768] Acoramidis has been in development since at least 2013. … [A264808] It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis.
Cardiolipin Biosynthesis CL(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
smpdb.ca/view/SMP0029994MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.